标准通道经皮肾镜取石术治疗孤立肾肾结石的长期安全性和有效性

目的: 探讨超声引导下标准通道经皮肾镜取石术(percutaneous nephrolithotomy,PCNL)治疗孤立肾肾结石患者的长期有效性和安全性。方法: 回顾性分析2008年9月至2014年6月于北京大学人民医院行PCNL治疗的22例孤立肾肾结石患者临床资料以及5年以上随访资料,记录围手术期相关指标、术后无石率(stone free rate,SFR)及并发症发生率,采用超声检查评估远期结石复发率,通过血肌酐及估计肾小球滤过率(estimated glomerular filtration rate, eGFR)评估肾功能情况。结果: 本组22例患者中,平均年龄为(50.3±11.8)岁,10例解剖性孤立肾,12例功能性孤立肾,中位结石直径为1.65(1.1~3.9) cm,全部为多发结石,包括7例鹿角形结石。术前的中位血肌酐为104.5(60.0~460.0) μmol/L,平均eGFR为(60.3±29.4) mL/min。平均手术时间为(88.2±42.0) min,各有11例单通道和双通道PCNL。术后第一天的中位血肌酐为102.0(63.0~364.0) μmol/L,平均eGFR为(58.0±25.1) mL/min,与术前相比差异均无统计学意义。术后平均住院时间为(8.7±5.2) d。本组有5例(22.7%)患者出现短期并发症,其中4例患者同时出现术后感染和大量出血,保守治疗后好转,1例患者出现胸膜损伤,行胸腔闭式引流后好转; 2例(9.1%)患者出现长期并发症,术后3个月发生输尿管狭窄,行球囊扩张术后好转;其余15例(68.2%)患者均未见并发症。中位随访时间为6.2(4.7~11.1)年,最近一次随访的中位血肌酐为104.0 (72.4~377.0) μmol/L,平均eGFR为(60.1±23.7) mL/min,与术前相比差异均无统计学意义,6例(27.3%)患者出现肾功能减退。术后初始和最终SFR分别为72.7%和100%; 6.2年的随访时间内9例(40.9%)患者结石复发,复发后共进行13次取石手术,最近一次随访的SFR为63.6%。结论: 本研究目前是国内外已有报道中关于孤立肾肾结石患者PCNL术后随访时间最长的研究,超声引导下标准通道PCNL治疗孤立肾肾结石是安全有效的,可以达到理想的SFR。长期随访结果表明仍有较高的结石复发率,但术后患者远期肾功能稳定,部分患者出现轻度肾功能减退。

Long-term analysis of safety and efficacy of standard percutaneous nephrolithotomy in patients with solitary kidneys

Objective: To evaluate the long-term efficacy and safety of ultrasound-guided percutaneous nephrolithotomy (PCNL) in the treatment of patients with solitary kidney stones. Methods: The clinical data of 22 patients with solitary kidney stones treated with PCNL in Peking University People’s Hospital from September 2008 to June 2014, with the follow-up data of more than 5 years were analyzed retrospectively. Perioperative indicators, postoperative stone free rate (SFR) and incidence of complications were recorded. Ultrasonography was used to evaluate the long-term stones recurrence rate. Serum creatinine and estimated glomerular filtration rate (eGFR) were used to assess the long-term renal function. Results: In this group of 22 patients, the average age was (50.3±11.8) years, with 10 cases of anatomic solitary kidneys, 12 functional solitary kidneys, and the median stone diameter was 1.65 (1.1-3.9) cm. All the patients had multiple stones, including 7 cases of staghorn stones. The median pre-operative serum creatinine was 104.5 (60.0-460.0) μmol/L, and the mean eGFR was (60.3±29.4) mL/min, showing no statistically significant difference compared with that before surgery. The mean operative time was (88.2±42.0) min, and there were 11 cases of single-channel and double-channel PCNL. The median serum creatinine on the first day after surgery was 102.0 (63.0-364.0) μmol/L, and the mean eGFR was (58.0±25.1) mL/min. The mean postoperative hospital stay was (8.7±5.2) days. In this group, 5 patients (22.7%) presented short-term complications, among which 4 patients presented postoperative infection and massive hemorrhage at the same time, which improved after conservative treatment, and 1 patient presented pleural injury and improved after closed thoracic drainage. Two patients (9.1%) developed long-term complications, and ureteral stricture occurred 3 months after operation, which improved after balloon dilatation. The median follow-up time was 6.2 (4.7-11.1) years. The median serum creatinine at the last follow-up was 104.0 (72.4-377.0) μmol/L, and the mean eGFR was (60.1±23.7) mL/min, showing no statistically significant difference compared with that before surgery. Renal function decreased in 6 patients (27.3%). Initial and final SFR were 72.7% and 100%, respectively. During the 6.2-year follow-up, 9 patients (40.9%) experienced recurrence of kidney stone. After stone recurrence, 13 lithotomy surgeries were performed, and the SFR by the latest follow-up was 63.6%. Conclusion: This study had the longest follow-up time for patients with solitary kidney stones after PCNL reported at home and abroad. Ultrasound-guided standard PCNL was safe and effective in the treatment of solitary kidney stones. Long-term follow-up results showed that the recurrence rate of kidney stones was still high, but the long-term renal function was stable after operation, and some patients showed mild renal function decline.